Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Coya Therapeutics, Inc.

< Previous 1 2 3 Next >
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA RDY
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics to Present at the LD Micro Investor Conference
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.